Hypoxia inducible factor-1 alpha (HIF-1 alpha) expression was correlated with the survival in patients with small cell lung cancer (SCLC)

T. C. Y. Tsao, L. Chang-Sheng, Y. Shun-Fa, C. Ya-Wen (Taichung, Changhua, Taiwan)

Source: Annual Congress 2010 - Prognostic factors for lung cancer
Session: Prognostic factors for lung cancer
Session type: Thematic Poster Session
Number: 3218
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. C. Y. Tsao, L. Chang-Sheng, Y. Shun-Fa, C. Ya-Wen (Taichung, Changhua, Taiwan). Hypoxia inducible factor-1 alpha (HIF-1 alpha) expression was correlated with the survival in patients with small cell lung cancer (SCLC). Eur Respir J 2010; 36: Suppl. 54, 3218

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008


Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007


The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Contribution of genetic polymorphism of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, to the susceptibility and severity of non-small cell lung cancer
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010

Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009


The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006

Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients
Source: Annual Congress 2009 - Pathology and immunology of COPD
Year: 2009


Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system
Source: Eur Respir J 2007; 30: Suppl. 51, 715s
Year: 2007

Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008

Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients
Source: Eur Respir J 2003; 22: Suppl. 45, 173s
Year: 2003

Downregulation of expression growth factor receptor induced by vector-based siRNA and its effect on radiosensitivity of pulmonary adenocarcinoma cell line
Source: Eur Respir J 2006; 28: Suppl. 50, 810s
Year: 2006